See more : CopperCorp Resources Inc. (CPER.V) Income Statement Analysis – Financial Results
Complete financial analysis of YSB Inc. (9885.HK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of YSB Inc., a leading company in the industry within the sector.
- Groupe Gorgé SA (GOE.PA) Income Statement Analysis – Financial Results
- Fineotex Chemical Limited (FCL.NS) Income Statement Analysis – Financial Results
- SDIC Zhonglu Fruit Juice Co.,Ltd. (600962.SS) Income Statement Analysis – Financial Results
- Analog Devices, Inc. (0HFN.L) Income Statement Analysis – Financial Results
- Jinhai International Group Holdings Limited (2225.HK) Income Statement Analysis – Financial Results
YSB Inc. (9885.HK)
Website: https://www.ysbang.cn
About YSB Inc.
YSB Inc. develops digital pharmaceutical platform for pharmaceutical companies, distributors, vendors, pharmacies, and primary healthcare institutions in China. It develops ClouDiagnos for diagnostic testing service; wePharmacy, a 24-hour access smart unmanned pharmaceutical booth that connects buyers and the end customers with pharmacist services; SaaS solutions; and YSB eLearn that provides online courses for the preparation of the pharmacist qualification examinations. The company also engages in the wholesale and retail of pharmaceutical and healthcare products. In addition, it provides medical testing services. The company was founded in 2015 and is headquartered in Guangzhou, China.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 16.97B | 14.27B | 10.09B | 6.06B |
| Cost of Revenue | 15.23B | 12.84B | 9.18B | 5.46B |
| Gross Profit | 1.74B | 1.43B | 913.83M | 608.79M |
| Gross Profit Ratio | 10.26% | 10.05% | 9.05% | 10.04% |
| Research & Development | 93.60M | 79.15M | 56.61M | 24.72M |
| General & Administrative | 332.60M | 286.79M | 207.01M | 156.22M |
| Selling & Marketing | 1.39B | 1.33B | 1.06B | 726.42M |
| SG&A | 1.72B | 1.61B | 1.27B | 882.63M |
| Other Expenses | -72.57M | -1.30B | -126.70M | -292.02M |
| Operating Expenses | 1.74B | 1.71B | 1.32B | 903.06M |
| Cost & Expenses | 16.97B | 14.55B | 10.50B | 6.36B |
| Interest Income | 49.14M | 42.66M | 27.90M | 25.31M |
| Interest Expense | 10.03M | 10.23M | 8.49M | 10.30M |
| Depreciation & Amortization | 134.07M | 135.03M | 102.26M | 82.40M |
| EBITDA | -3.07B | -1.35B | -392.32M | -483.57M |
| EBITDA Ratio | -18.07% | -9.46% | -3.85% | -7.72% |
| Operating Income | -70.03M | -1.49B | -490.75M | -550.35M |
| Operating Income Ratio | -0.41% | -10.41% | -4.86% | -9.07% |
| Total Other Income/Expenses | -3.14B | -11.15M | -12.33M | -25.93M |
| Income Before Tax | -3.21B | -1.50B | -503.07M | -576.27M |
| Income Before Tax Ratio | -18.91% | -10.49% | -4.98% | -9.50% |
| Income Tax Expense | -3.69M | 3.17M | -1.45M | -4.56M |
| Net Income | -3.21B | -1.50B | -501.62M | -571.71M |
| Net Income Ratio | -18.89% | -10.51% | -4.97% | -9.43% |
| EPS | -8.30 | -11.97 | -4.00 | -4.56 |
| EPS Diluted | -8.30 | -11.97 | -4.00 | -4.56 |
| Weighted Avg Shares Out | 386.10M | 125.32M | 125.32M | 125.32M |
| Weighted Avg Shares Out (Dil) | 386.10M | 125.32M | 125.32M | 125.32M |
Source: https://incomestatements.info
Category: Stock Reports